Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube.

Vicus D, Finch A, Cass I, Rosen B, Murphy J, Fan I, Royer R, McLaughlin J, Karlan B, Narod SA.

Gynecol Oncol. 2010 Sep;118(3):299-302. doi: 10.1016/j.ygyno.2010.05.011. Epub 2010 Jun 8.

PMID:
20570322
2.

Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.

Vicus D, Finch A, Rosen B, Fan I, Bradley L, Cass I, Sun P, Karlan B, McLaughlin J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.

Gynecol Oncol. 2010 Aug 1;118(2):155-9. doi: 10.1016/j.ygyno.2010.03.009. Epub 2010 May 10.

PMID:
20452659
3.

A genetic epidemiological study of carcinoma of the fallopian tube.

Aziz S, Kuperstein G, Rosen B, Cole D, Nedelcu R, McLaughlin J, Narod SA.

Gynecol Oncol. 2001 Mar;80(3):341-5.

PMID:
11263928
4.

BRCA2 germline mutations in primary cancer of the fallopian tube.

Casarsa S, Puglisi F, Baudi F, De Paola L, Venuta S, Piga A, Di Loreto C, Marchesoni D, D'Elia AV, Damante G.

Oncol Rep. 2004 Aug;12(2):313-6.

PMID:
15254695
5.

Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.

Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A.

J Natl Cancer Inst. 2001 Aug 15;93(16):1215-23.

PMID:
11504767
7.
8.

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.

Clin Cancer Res. 2002 Dec;8(12):3776-81.

9.

Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases.

Malone KE, Daling JR, Neal C, Suter NM, O'Brien C, Cushing-Haugen K, Jonasdottir TJ, Thompson JD, Ostrander EA.

Cancer. 2000 Mar 15;88(6):1393-402.

PMID:
10717622
10.

BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?

Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY.

Obstet Gynecol. 2005 Dec;106(6):1327-34.

PMID:
16319259
11.

Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations.

Zweemer RP, van Diest PJ, Verheijen RH, Ryan A, Gille JJ, Sijmons RH, Jacobs IJ, Menko FH, Kenemans P.

Gynecol Oncol. 2000 Jan;76(1):45-50.

PMID:
10620440
12.

Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.

Schorge JO, Mahoney NM, Miller DS, Coleman RL, Muller CY, Euhus DM, Tomlinson GE.

Gynecol Oncol. 2001 Nov;83(2):383-7.

PMID:
11606101
13.

BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.

Bergthorsson JT, Ejlertsen B, Olsen JH, Borg A, Nielsen KV, Barkardottir RB, Klausen S, Mouridsen HT, Winther K, Fenger K, Niebuhr A, Harboe TL, Niebuhr E.

J Med Genet. 2001 Jun;38(6):361-8.

14.

Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.

Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet JS, Narod S.

J Natl Cancer Inst. 1999 Jul 21;91(14):1241-7.

PMID:
10413426
15.

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.

Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, Wilbanks G, Nicosia S, Cantor A, Sutphen R.

Cancer. 2005 Dec 15;104(12):2807-16.

16.

Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.

Rebbeck TR, Kauff ND, Domchek SM.

J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442. Epub 2009 Jan 13.

17.

Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.

Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, Narod SA.

J Clin Oncol. 2010 Jan 20;28(3):387-91. doi: 10.1200/JCO.2009.25.0712. Epub 2009 Dec 14.

PMID:
20008623
18.

BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.

Lavie O, Hornreich G, Ben-Arie A, Rennert G, Cohen Y, Keidar R, Sagi S, Lahad EL, Auslander R, Beller U.

Gynecol Oncol. 2004 Feb;92(2):521-4.

PMID:
14766242
19.

Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening.

Palomba G, Pisano M, Cossu A, Budroni M, Dedola MF, Farris A, Contu A, Baldinu P, Tanda F, Palmieri G.

Cancer. 2005 Sep 15;104(6):1172-9.

20.

Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.

Bonadona V, Sinilnikova OM, Chopin S, Antoniou AC, Mignotte H, Mathevet P, Brémond A, Martin A, Bobin JY, Romestaing P, Raudrant D, Rudigoz RC, Léoné M, Chauvin F, Easton DF, Lenoir GM, Lasset C.

Genes Chromosomes Cancer. 2005 Aug;43(4):404-13.

PMID:
15887246

Supplemental Content

Support Center